ABO Blood Group Antigen Changes in Acute Myeloid Leukemia and No Significant Association With<i>RUNX1</i>and<i>GATA2</i>Somatic Variants

Jeong, In Du; Seo, Jae Hwa; Choi, Sooin; Kim, Hyun-Young; Cho, Duck

doi:10.3343/alm.2023.43.6.635

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study investigating the association of RUNX1 and GATA2 with this phenomenon among patients with AML found no significant correlation between these genes and ABO antigen weakness. 20 To address the discrepancies observed in previous studies, this study aimed to identify genes associated with the phenomenon by analyzing genetic test results from patients. The results revealed a significant association between RUNX1 and ABO antigen weakness, whereas no association was identified with GATA2 .…”

Section: Discussionmentioning

confidence: 99%

CEBPA double mutations associated with ABO antigen weakness in hematologic diseases

Choi,

Kim,

Suh

et al. 2024

Blood Advances

View full text Add to dashboard Cite

The ABO antigen weakness is rarely observed in ABO typing for transfusion. Hematologic diseases and associated gene mutations have been suggested as potential causes of this phenomenon, yet the precise etiology has not been elucidated. Through ABO typing and genetic analysis data conducted over 7 years, we have reconfirmed the association between ABO antigen weakness and hematologic diseases, especially acute myeloid leukemia (odds ratio (OR) 2.55, 95% confidence interval (CI) 1.12-5.83) and myelodysplastic syndrome (OR 6.94, 95% CI 2.86-16.83), and discovered previously unidentified candidate genes, CEBPA (OR 43.70, 95% CI 18.12-105.40), NRAS (OR 3.37, 95% CI 1.46-7.79), U2AF1 (OR 8.12, 95% CI 2.86-23.03) and PTPN11 (OR 4.52, 95% CI 1.51-13.50), seemingly associated with this phenomenon. Among these, CEBPA double mutations displayed a significant association, with ABO antigen weakness being observed in 20 out of the 25 individuals (80.0%) possessing these mutations. From this study, new factors associated with ABO antigen weakness have been identified.

show abstract

Section: Discussionmentioning

confidence: 99%

CEBPA double mutations associated with ABO antigen weakness in hematologic diseases

Choi,

Kim,

Suh

et al. 2024

Blood Advances

View full text Add to dashboard Cite

show abstract

CEBPA and GATA2 mutation and a transient blood group discrepancy in a patient with acute myeloid leukaemia

Flores‐Morán,

Fuste

2024

Transfusion Medicine

View full text Add to dashboard Cite

Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation

Yurtsever,

Lee,

Pinatti

et al. 2024

Immunohematology

View full text Add to dashboard Cite

ABO group testing is critical for allogeneic stem cell transplantation because mismatches can cause both transfusion and engraftment challenges. Even with ABO-matched donor-recipient pairs, ABO group determination may provide valuable insight into allograft status. Herein, we report a case of a 76-year-old female patient with myeloid neoplasm who underwent ABO-matched stem cell transplantation and in whom mixed-field ABO antigen expression during routine follow-up testing post-transplantation was the first sign of a change in transplant graft status; the mixed-field findings pre-dated changes in formal chimerism testing. This case underscores the potential of mixed-field ABO typing as an early indicator of disease recurrence in ABO-matched stem cell transplants and suggests that, in such cases, more sensitive forms of chimerism testing and/or closer monitoring for disease recurrence, particularly in the clinical setting of myeloid neoplasms, may be warranted.

show abstract

ABO Blood Group Antigen Changes in Acute Myeloid Leukemia and No Significant Association WithRUNX1andGATA2Somatic Variants

Cited by 3 publications

References 10 publications

CEBPA double mutations associated with ABO antigen weakness in hematologic diseases

CEBPA double mutations associated with ABO antigen weakness in hematologic diseases

CEBPA and GATA2 mutation and a transient blood group discrepancy in a patient with acute myeloid leukaemia

Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation

Contact Info

Product

Resources

About